QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mezei, O. Articles by Shay, N. Search for Related Content PubMed PubMed Citation Articles by Mezei, O. Articles by Shay, N. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Substance via MeSH Medline Plus Health Information Diabetes Herbal Medicine

---

Biochemical and Molecular Actions of Nutrients

Soy Isoflavones Exert Antidiabetic and Hypolipidemic Effects through the PPAR Pathways in Obese Zucker Rats and Murine RAW 264.7 Cells

Department of Biological Sciences, University of Notre Dame, Notre Dame, IN 46556 and ^* Departments of Animal Science, Food & Nutrition, and Physiology, Southern Illinois University, Carbondale, IL 62901

²To whom correspondence should be addressed. E-mail: nshay1{at}nd.edu.

	ABSTRACT

TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION LITERATURE CITED

 
The hypocholesterolemic and anti-atherosclerotic mechanism by which soy may exert a beneficial effect remains unclear. Peroxisome-proliferator activated receptors (PPAR) are promiscuous nuclear receptors that regulate the transcription of genes involved in lipid and glucose homeostasis and lipid metabolism within the cell. We hypothesize that the isoflavones improve lipid and glucose metabolism by acting as an antidiabetic PPAR agonist. Male and female obese Zucker rats (OZR) were used as a model of Type 2 diabetes, and OZR fed a high isoflavone soy protein diet displayed improvements in lipid metabolism consistent with results in humans treated with antidiabetic PPAR agonists such as the fibrates or glitazones. Liver triglyceride and cholesterol concentrations were lower in all OZR fed high-isoflavone soy protein diets than in rats fed low-isoflavone and casein diets (P < 0.05). Concurrently, PPAR-directed gene expression was evaluated in a cell culture model. An isoflavone-containing soy extract doubled PPAR-directed gene expression (P < 0.05) in RAW 264.7 cells containing either a PPAR or PPAR expression plasmid. A similar induction was observed when the soy isoflavones genistein or daidzein were used to treat cells. Both isoflavones doubled PPAR-directed gene expression (P < 0.05), whereas they increased PPAR-directed gene expression 200–400% (P < 0.05). This study suggests that soy isoflavones improve lipid metabolism, produce an antidiabetic effect, and activate PPAR receptors.

KEY WORDS: • PPAR • cholesterol • diabetes • isoflavones • soy

Soy intake has been linked to improved blood lipid levels in humans and animals and decreased arterial fatty streaks in animals, thereby reducing the risk of developing atherosclerosis (1 –6 ). However, the physiological mechanism by which soy may improve blood lipid profiles has been the subject of speculation and investigated but is still not known with any certainty. It is unclear which soy components may contribute to the lipid-lowering property of soy, and numerous studies have been conducted to determine which components of soy exert bioactive effects (3 ,7 ). Soy components include protein, lipids, fiber and phytochemicals including isoflavones. Some researchers have focused on isoflavones as an important bioactive component of soy. The three main isoflavones found in soybeans are genistein, daidzein and glycitein (3 ).

Considerable research effort has focused on isoflavones as the main hypolipidemic agent in soy because of their antioxidative and mild estrogenic activity (4 ,8 ,9 ). In fact, some studies have shown that removal of the isoflavone-containing fraction of soy protein results in the loss of soy’s beneficial effect on blood lipids (10 ,11 ). However, other recent studies reported minimal effects of soy isoflavones on blood lipid levels alone (12 –15 ). Because of these conflicting results, it is possible that isoflavones exert some of their beneficial effects mainly when they are part of an intact soy source (7 ,16 ).

Recent studies have also provided evidence that soy consumption alleviates some of the symptoms associated with Type 2 diabetes such as insulin resistance and glycemic control (17 ,18 ). Some of these effects may be the end result of the improved blood lipid profile caused by soy consumption. However, it remains a possibility that soy has a positive and direct effect on the management of diabetes by some yet-unrecognized mechanism.

One such mechanism may be by peroxisome-proliferator activated receptors (PPAR), nuclear receptors that participate in cellular lipid homeostasis and insulin action (19 –23 ). Upon ligand binding, PPAR are activated and bind to peroxisome-proliferator response element (PPRE) sequences located within the promoters of PPAR-regulated genes (20 ,24 ). PPAR are "promiscuous" receptors, so named because they can be activated by many different ligands. Ligands for PPAR include some unsaturated fatty acids and their derivatives as well as glitazones, insulin-sensitizing drugs used to treat Type 2 diabetes (20 ,25 ). Ligands for PPAR include some saturated and unsaturated fatty acids as well as the group of drugs termed fibrates, which are hypolipidemic agents used to manage elevated blood lipid levels and Type 2 diabetes (26 ). Generally, PPAR controls the transcription of many genes involved in lipid catabolism, whereas PPAR controls the expression of genes involved in adipocyte differentiation and insulin sensitization (20 ). Together, activation of PPAR and PPAR increases ß-oxidation and insulin sensitization, whereas blood and liver lipid concentrations are typically reduced. The increase in adipocyte differentiation attributed to PPAR activation often results in weight gain because of increased body fat, resulting in the paradoxical effect of PPAR agonist treatment: increased fat mass alongside improvements in other metabolic lipid variables (27 ).

Considering the promiscuous ligand binding properties of PPAR and the effects of PPAR on lipid metabolism, we hypothesized that soy isoflavones exert a beneficial hypolipidemic and antidiabetic effect by activation of the PPAR receptors.

	MATERIALS AND METHODS

TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION LITERATURE CITED

 
Rat diets.

Experimental diets were prepared and feed consumption was measured as described previously (28 ,29 ). Only the protein component of the diet was modified; all other nutrients were held constant and based on AIN-93 guidelines (30 ). The protein sources used were high-isoflavone soy protein (HIS), low-isoflavone soy protein (LIS) and casein (C) (Table 1).

The Southern Illinois University Animal Care and Use Committee approved all rat studies. Nine-wk-old male and female obese Zucker rats (OZR; Harlan, Indianapolis, IN) were acclimated to the animal facility for 2 wk and all were then randomly assigned to C, LIS or HIS diets (Table 1). Rats consumed food and water ad libitum, and food intake was recorded daily. Body weight was recorded weekly. Male OZR consumed the diets for 8 wk and the female OZR consumed the diets for 11 wk. Blood was collected by cardiac puncture; a bilateral thoracotomy followed to assure death. Blood from fasting rats was collected by cardiac puncture, heparinized and centrifuged. Plasma aliquots were then stored at -70°C. The feed-efficiency ratio (FER) was determined. Rats and organs were examined for any overt pathological conditions.

Liver and plasma lipid concentrations.

Liver and plasma lipids were analyzed as previously described (28 ). Briefly, total liver lipids were extracted; total and unesterified cholesterol concentrations were determined colorimetrically by an enzymatic procedure, and cholesteryl esters were calculated by differences (31 ). Liver triglycerides were measured by a procedure using the Hantzch reaction. Plasma triglycerides were measured by the use of a commercial kit (#320-A; Sigma, St. Louis, MO).

Glucose tolerance test (GTT).

During wk 9 and 10, female OZR were deprived of food overnight, anesthetized with ether and bled through the orbital sinus immediately before administration of an intraperitoneal (i.p.) glucose load (2 g glucose/kg body), and at 15, 30, 60, 90, 120, 150, 180, 210 and 240 min later. At the end of the GTT the females were killed. Plasma glucose was measured by use of a commercial glucose kit (#635; Sigma).

Cell culture and reagents.

The effect of various soy phytochemicals on PPAR-mediated gene expression was tested in murine macrophage-like RAW 264.7 cells (ATCC, Rockville, MD). G-2535, a soy extract containing unconjugated soy isoflavones, was from Protein Technologies International (St. Louis, MO), and Prevastein HC, a soy extract containing conjugated soy isoflavones was from Cognis (LaGrange, IN). Genistein, daidzein, glycitein and clofibrate were purchased from Sigma. Dimethyl sulfoxide (DMSO) was purchased from Fisher Scientific (Pittsburgh, PA). RAW 264.7 cells were grown in high glucose Dulbecco’s modified Eagle’s medium with pyruvate (GIBCO, Gaithersburg, MD) containing 10% fetal bovine serum and 1% penicillin-streptomycin. Cells were maintained at 37°C, 5% CO₂ and 100% relative humidity.

Plasmid constructs.

To evaluate PPAR-directed gene expression, we used the pTK.PPRE3x luciferase expression plasmid, which is regulated by the PPRE-containing acyl CoA oxidase promoter (32 ). To study PPAR- and PPAR-regulated gene expression, a pCMX.PPAR or a pCMX.PPAR expression plasmid was transiently cotransfected into cells (32 ). The ß-galactosidase plasmid (Promega, Madison, WI) was used as an internal control to monitor transfection efficiency.

Transfections.

Near-confluent RAW 264.7 cells were removed from culture plates by use of phosphate-buffered saline containing 10 mmol/L EDTA and replated onto six-well plates at 8.4 x 10⁵ cells/well. Transient cotransfections were performed 18 h later by use of 20 µL of lipofectamine and 9 µL lipofectamine plus reagents per well (Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol. Each well was transfected with 1.5 µg of the pTK.PPRE3x reporter construct, 1.5 µg of the pCMX.PPAR or the pCMX.PPAR expression plasmids, and 1.5 µg of the ß-galactosidase plasmid. After 6 h of transfection, cell media was replaced with media containing 0.5% fetal bovine serum and 1% penicillin-streptomycin.

Cell treatments.

Transiently cotransfected cells were kept in the 0.5% serum media for 12 h and treated with one of the following: G-2535, Prevastein HC, genistein, daidzein, glycitein, or vehicle serving as a control (consisting of DMSO at less than 0.1% v/v and/or ethanol at less than 0.9% v/v). Positive controls were 20 µmol/L of pioglitazone (for PPAR) or 100 µmol/L of clofibrate (for PPAR). Cells were harvested after 6, 9, 12, or 24 h by use of Reporter Lysis Buffer (Promega); lysates were centrifuged at 12,000 x g for 2 min at 4°C and the supernatants stored at -70°C. Luciferase activity was determined with a TR717 Microplate Luminometer (Applied Biosystems, Foster City, CA) by use of the luciferase assay reagent according to the manufacturer’s protocol (Promega). The ß-galactosidase activity was determined by use of o-nitrophenyl-ß-D-galactopyranoside as a substrate, according to the manufacturer’s protocol (Promega). ß-Galactosidase activity was assayed at 420 nm (Bio-Tek Instruments, Winooski, VT). Every transfection experiment also included samples not transfected with plasmids to measure baseline levels for the luciferase and ß-galactosidase assays. Luciferase assay activity was normalized to ß-galactosidase activity for each well in each experiment to control for transfection efficiency. All luciferase values are expressed relative to the mean of the vehicle control.

Statistical analysis.

All rat experiments used a block-randomized design. Data were analyzed by one-way ANOVA and post hoc comparisons (LSD) were made (significance at P 0.05) when appropriate. Data are presented as means ± SEM. For the cell experiments, each time-course experiment was initially analyzed by a two-way ANOVA, and when there were significant differences, individual time points were further analyzed post hoc by use of Kruskal–Wallis ANOVA on ranks. All other cell experiments were analyzed by Kruskal–Wallis ANOVA on ranks unless otherwise stated.

	RESULTS

TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION LITERATURE CITED

 
Rat studies.

Female OZR fed the HIS diet gained more body weight than both the LIS- and C-fed rats (P < 0.05) (Table 2). This weight change was accompanied by a concomitant increase in FER (P < 0.05). The male OZR fed the HIS diet demonstrated similar nonsignificant trends in weight change and FER (P > 0.1). There was no increase in visceral fat weight in either the male or female OZR fed the HIS diet (Table 2).

View larger version (20K): [in this window] [in a new window]   FIGURE 1 Glucose tolerance test (GTT) in female obese Zucker rats (OZR) fed casein (C), low-isoflavone soy protein (LIS) or high-isoflavone soy protein (HIS) diets for 11 wk. Values are means ± SEM, n = 4. Means at a time without a common letter differ, P < 0.05.

G-2535 induced PPAR-regulated luciferase activity in RAW 264.7 cells expressing a PPRE-containing reporter and PPAR expression plasmids (Fig. 2A ) (P < 0.001). When individual time points were analyzed, G-2535 treatment-induced luciferase activity was greater than in cells treated with the vehicle (control) or clofibrate (P < 0.05).

View larger version (25K): [in this window] [in a new window]   FIGURE 2 The effect of an unconjugated isoflavone-containing soy extract on PPAR activation. Luciferase activity was regulated by the PPRE-containing reporter plasma and was cotransfected into RAW 264.7 cells using the PPAR (A) or PPAR (B) expression plasmids. Cells were incubated with a vehicle (VEH), 2.5 mg/L G-2535 (U-SOY), clofibrate (CLO, A) or pioglitazone (PIO, B) after transfection. Values are means ± SEM, n = 7–11. Means at a time without a common letter differ, P < 0.05.

To determine the effects of unconjugated compared to conjugated isoflavones and individual isoflavones, cells were treated with vehicle, a positive control (clofibrate or pioglitazone), G-2535, Prevatein HC, genistein, daidzein or glycitein for 24 h. Cells containing the PPRE-reporter and PPAR expression plasmids significantly increased luciferase activity when treated with G-2535 soy extract (220% greater), genistein (140% greater) and daidzein (160% greater) compared to vehicle-treated cells (all P < 0.05) (Fig. 3A ). PPRE-directed gene expression was not increased by treatment with Prevastein HC or glycitein.

View larger version (22K): [in this window] [in a new window]   FIGURE 3 The effect of isoflavone-containing soy extracts and soy isoflavones on PPAR activation. Luciferase activity was regulated by the PPRE-containing reporter plasma and was cotransfected into RAW 264.7 cells using the PPAR (A) or PPAR (B) expression plasmids. Cells were incubated with either a vehicle (VEH), clofibrate (CLO), pioglitazone (PIO), 2.5 mg/L G-2535 (U-SOY) or Prevastein HC (C-SOY), 9.3 µmol/L genistein (GEN), 9.8 µmol/L daidzein (DAID) or 8.8 µmol/L glycitein (GLYC). Values are means ± SEM, n = 7–8. Means without a common letter differ (P < 0.05).

	DISCUSSION

TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION LITERATURE CITED

 
We have demonstrated that consumption of an HIS diet improves lipid metabolism and glucose tolerance in male and female OZR and glucose tolerance in female OZR, especially when directly compared to OZR fed the LIS diet. Further, we showed that isoflavone-containing soy extracts and individual soy isoflavones activated PPAR-mediated gene expression. These data suggest that, compared to LIS, the increased level of isoflavones present in the HIS diet improved lipid metabolism and glucose tolerance by PPAR activation. We chose the OZR for the in vivo study because it is an established animal model, especially with respect to diabetes and the metabolic syndrome (33 ). When fed HIS diets, OZR had an increased FER, and in all OZR fed HIS compared to OZR fed LIS (n = 12 each) diets, weight gain was greater (P < 0.05). In contrast to increased body weight, liver weight, liver cholesterol and liver triglyceride concentrations were all reduced in HIS-fed compared to LIS-fed OZR. Additionally, HIS-fed female OZR had significantly improved glucose tolerance compared to LIS- or C-fed OZR. These data are consistent with PPAR agonist actions and previous research published in OZR (27 ,28 ,34 ). At this time, we are unable to explain the increase in plasma triglycerides in female OZR fed a HIS diet compared to both the C- and LIS-fed rats. This same increase was described previously when Zucker rats were fed a soy diet (35 ).

In a comparison of HIS- and LIS-fed OZR, plasma cholesterol levels were significantly lower only in the females. Interestingly, a recent report describes results in Golden Syrian F₁B hybrid hamsters, in which males fed a HIS diet had reduced plasma LDL-cholesterol, whereas the females’ cholesterol concentrations did not change (36 ). Species and sex differences may contribute to the differences in animal studies investigating the plasma cholesterol–lowering property of soy. Future research should further investigate gender-based effects of soy isoflavones. Furthermore, the OZR is not the ideal model for studying atherosclerosis and plasma cholesterol concentrations (33 ).

Our animal studies demonstrated metabolic changes suggestive of a PPAR agonist-like effect of soy isoflavones. Thus, we performed cell culture studies to determine whether isoflavones could influence PPAR action. Cell treatments were designed to resemble concentrations similar to the plasma concentrations of isoflavones measured in vivo (37 ,38 ). Exposing cells to a soy extract containing conjugated isoflavones did not affect activation (Fig. 2) . However, when cells were exposed to an unconjugated isoflavone-containing soy extract, PPAR-mediated gene expression was increased. Tested individually, genistein and daidzein activated PPAR and PPAR, whereas glycitein had no effect. Our results are consistent with a recent study reporting genistein-induced activation of PPAR in KS483 cells (39 ). Unlike the highly specific estrogen receptors, PPAR bind a wide number of ligands and directly affect lipid metabolism by enhancing transcription of PPAR-regulated genes. This "promiscuous" binding activity suggests that phytochemicals including soy isoflavones bind and activate PPAR and PPAR (40 ).

In conclusion, an isoflavone-containing soy diet improved the diabetic phenotype of male and female OZR. Moreover, cell studies provided direct evidence that soy isoflavones affect both PPAR- and PPAR-directed gene expression. This study suggests that soy isoflavones exert a beneficial effect on lipid and glucose metabolism through activation of the PPAR receptors.

	ACKNOWLEDGMENTS

 
We thank David Mangelsdorf for kindly donating the Tk.PPRE3x luciferase reporter construct and the PPAR and PPAR expression plasmids and David D. Moore for helpful discussion. We acknowledge Nancy Henry, Mikelle Roeder, Carla Stiglitz and Beth Kinney for their support. We also thank Protein Technologies International for donation of G-2535 soy extract product and Richard Staack for donation of Prevastein HC.

	FOOTNOTES

 
¹ Awards from Protein Technologies International, the American Heart Association, and the Illinois Council on Food and Agricultural Research supported this work.

³ Abbreviations used: C, casein; FER, feed-efficiency ratio; GTT, glucose tolerance test; HIS, high isoflavone-containing soy protein; LIS, low isoflavone-containing soy protein; OZR, obese Zucker rat; PPAR, peroxisome-proliferator activated receptor; PPRE, peroxisome-proliferator response element.

Manuscript received 20 December 2002. Initial review completed 7 January 2003. Revision accepted 27 January 2003.

	LITERATURE CITED

TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION LITERATURE CITED

 

1. Adams, M., Golden, D., Anthony, M., Register, T. & Williams, J. K. (2002) The inhibitory effect of soy protein isolate on atherosclerosis in mice does not require the presence of LDL receptors or alteration of plasma lipoproteins. J. Nutr. 132:43-49.[Abstract/Free Full Text]

2. Lichtenstein, A. H. (2001) Got soy?. Am. J. Clin. Nutr. 73:667-668.[Free Full Text]

3. Clarkson, T. B. (2002) Soy, soy phytoestrogens and cardiovascular disease. J. Nutr. 132:566S-569S.[Abstract/Free Full Text]

4. Anthony, M. S. (2000) Soy and cardiovascular disease: cholesterol lowering and beyond. J. Nutr. 130:662S-663S.

5. Yamakoshi, J., Piskula, M. K., Izumi, T., Tobe, K., Saito, M., Kataoka, S., Obata, A. & Kikuchi, M. (2000) Isoflavone aglycone-rich extract without soy protein attenuates atherosclerosis development in cholesterol-fed rabbits. J. Nutr. 130:1887-1893.[Abstract/Free Full Text]

6. Iqbal, M. J., Yaegashi, S., Ahsan, R., Lightfoot, D. A. & Banz, W. J. (2002) Differentially abundant mRNAs in rat liver in response to diets containing soy protein isolate. Physiol. Genomics 11:219-226.[Abstract/Free Full Text]

7. Nestel, P. (2002) Role of soy protein in cholesterol-lowering: how good is it?. Arterioscler. Thromb. Vasc. Biol. 22:1743-1744.[Free Full Text]

8. Polkowski, K. & Mazurek, A. P. (2000) Biological properties of genistein. A review of in vitro and in vivo data. Acta Pol. Pharm. 57:135-155.[Medline]

9. Wilson, T., March, H., Banz, W. J., Hou, Y., Adler, S., Meyers, C. Y., Winters, T. A. & Maher, M. A. (2002) Antioxidant effects of phyto- and synthetic-estrogens on cupric ion-induced oxidation of human low-density lipoproteins in vitro. Life Sci. 70:2287-2297.[Medline]

10. Anthony, M. S., Clarkson, T. B. & Williams, J. K. (1998) Effects of soy isoflavones on atherosclerosis: potential mechanisms. Am. J. Clin. Nutr. 68:1390S-1393S.[Abstract]

11. Crouse, J. R., 3rd, Morgan, T., Terry, J. G., Ellis, J., Vitolins, M. & Burke, G. L. (1999) A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins. Arch. Intern. Med. 159:2070-2076.[Abstract/Free Full Text]

12. Lichtenstein, A. H, Jalbert, S. M., Adlercreutz, H., Goldin, B. R., Rasmussen, H., Schaefer, E. J. & Ausman, L. M. (2002) Lipoprotein response to diets high in soy or animal protein with and without isoflavones in moderately hypercholesterolemic subjects. Arterioscler. Thromb. Vasc. Biol. 22:1852-1858.[Abstract/Free Full Text]

13. Gardner, C. D., Newell, K. A., Cherin, R. & Haskell, W. L. (2001) The effect of soy protein with or without isoflavones relative to milk protein on plasma lipids in hypercholesterolemic postmenopausal women. Am. J. Clin. Nutr. 73:728-735.[Abstract/Free Full Text]

14. Simons, L. A., von Konigsmark, M., Simons, J. & Celermajer, D. S. (2000) Phytoestrogens do not influence lipoprotein levels or endothelial function in healthy, postmenopausal women. Am. J. Cardiol. 85:1297-1301.[Medline]

15. Sirtori, C. R. (2001) Risks and benefits of soy phytoestrogens in cardiovascular diseases, cancer, climacteric symptoms and osteoporosis. Drug Saf. 24:665-682.[Medline]

16. Jenkins, D.J.A., Kendall, C.W.C., Jackson, C.-J.C., Connelly, P. W., Parker, T., Faulkner, D., Vidgen, E., Cunnane, S. C., Leiter, L. A. & Josse, R. G. (2002) Effects of high- and low-isoflavone soyfoods on blood lipids, oxidized LDL, homocysteine, and blood pressure in hyperlipidemic men and women. Am. J. Clin. Nutr. 76:365-372.[Abstract/Free Full Text]

17. Jayagopal, V., Albertazzi, P., Kilpatrick, E. S., Howarth, E. M., Jennings, P. E., Hepburn, D. A. & Atkin, S. L. (2002) Beneficial effects of soy phytoestrogen intake in postmenopausal women with Type 2 diabetes. Diabetes Care 25:1709-1714.[Abstract/Free Full Text]

18. Bhathena, S. J. & Velasquez, M. T. (2002) Beneficial role of dietary phytoestrogens in obesity and diabetes. Am. J. Clin. Nutr. 76:1191-1201.[Abstract/Free Full Text]

19. Chinetti, G., Fruchart, J. C. & Staels, B. (2000) Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Infamm. Res. 49:497-505.

20. Neve, B. P., Fruchart, J. C. & Staels, B. (2000) Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem. Pharmacol. 60:1245-1250.[Medline]

21. de Villiers, W.J.S. & Smart, E. J. (1999) Macrophage scavenger receptors and foam cell formation. J. Leukoc. Biol. 66:740-746.[Abstract]

22. Napoli, C., de Nigris, F. & Palinski, W. (2001) Multiple role of reactive oxygen species in the arterial wall. J. Cell. Biochem. 82:674-682.[Medline]

23. Nagy, L., Tontonoz, P., Alvarez, J.G.A., Chen, H. & Evans, R. M. (1998) Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR. Cell 93:229-240.[Medline]

24. Qi, C., Yijun, Z. & Reddy, J. K. (2000) Peroxisome proliferator-activated receptors, coactivators, and downstream targets. Cell. Biochem. Biophys. 32:187-204.

25. Ricote, M. & Glass, C. K. (2001) New role for PPARs in cholesterol homeostasis. Trends Pharmacol. Sci. 22:441-443.[Medline]

26. Gotto, A. M. (2002) Lipid management in diabetic patients: lessons from prevention trials. Am. J. Med. 112(suppl. 8A):19S-26S.

27. Picard, F. & Auwerx, J. (2002) PPAR and glucose homeostasis. Annu. Rev. Nutr. 22:167-197.[Medline]

28. Peluso, M. R., Winters, T. A., Shanahan, M. F. & Banz, W. J. (2000) A cooperative interaction between soy protein and its isoflavone-enriched fraction lowers hepatic lipids in male obese Zucker rats and reduces blood platelet sensitivity in male Sprague-Dawley rats. J. Nutr. 130:2333-2342.[Abstract/Free Full Text]

29. O’Connor, T. P., Liesen, D. A., Mann, P. C., Rolando, L. & Banz, W. J. (2002) A high isoflavone soy protein diet and intravenous genistein delay rejection of rat cardiac allografts. J. Nutr. 132:2283-2287.[Abstract/Free Full Text]

30. Reeves, P. G., Nielsen, F. H. & Fahey, G. C., Jr (1993) AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J. Nutr. 123:1939-1951.

31. Allain, C. C., Poon, L. S., Chan, C.S.G., Richmond, W. & Fu, P. C. (1974) Enzymatic determination of total serum cholesterol. Clin. Chem. 20:470-475.[Abstract]

32. Kliewer, S. A., Forman, B. M., Blumberg, B., Ong, E. S., Borgmeyer, U., Mangelsdorf, D. J., Umesono, K. & Evans, R. M. (1994) Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. U.S.A. 91:7355-7359.[Abstract/Free Full Text]

33. Mathe, D. (1995) Dyslipidemia and diabetes: animal models. Diabetes Metab. 21:106-111.

34. Xie, Y., Yang, Q. & DePierre, J. W. (2002) The effects of peroxisome proliferators on global lipid homeostasis and the possible significance of these effects to other responses to these xenobiotics: an hypothesis. Ann. N. Y. Acad. Sci. 973:17-25.[Medline]

35. Maddox, D. A., Alavi, F. K., Silbvrenick, E. M. & Zawada, E. T. (2002) Protective effects of a soy diet in preventing obesity-linked renal disease. Kidney Int. 61:96-104.[Medline]

36. Blair, R. M., Appt, S. E., Bennetau-Pelissero, C., Clarkson, T. B., Anthony, M. S., Lamothe, V. & Potter, S. M. (2002) Dietary soy and soy isoflavones have gender-specific effects on plasma lipids and isoflavones in golden Syrian f(1)b hybrid hamsters. J. Nutr. 132:3585-3591.[Abstract/Free Full Text]

37. Setchell, K.D.R., Brown, N. M., Desaj, P., Zimmer-Nechemias, L., Wolf, B. E., Brahear, W. T., Kirschner, A. S., Cassidy, A. & Heubi, J. E. (2001) Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J. Nutr. 131:1362S-1375S.[Abstract/Free Full Text]

38. Shelnutt, S. R., Cimino, C. O., Wiggins, P. A., Ronis, M.J.J. & Badger, T. M. (2002) Pharmacokinetics of the glucuronide and sulfate conjugates of genistein and daidzein in men and women after consumption of a soy beverage. Am. J. Clin. Nutr. 75:588-594.

39. Dang, Z.-C., Audinot, V., Papapoulos, S. E., Boutin, J. A. & Löwik, C.W.G.M. (2003) Peroxisome proliferator-activated receptor (PPAR) as a molecular target for the soy phytoestrogen genistein. J. Biol. Chem. 278:962-967.[Abstract/Free Full Text]

40. Xu, H. E., Lambert, M. H., Montana, V. G., Plunket, K. D., Moore, L. B., Collins, J. L., Oplinger, J. A., Kliewer, S. A., Gampe, R. T., Jr, McKee, D. D., Moore, J. T. & Willson, T. M. (2001) Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. U.S.A. 98:3919-3924.

This article has been cited by other articles:

				M. J. Ronis, Y. Chen, J. Badeaux, and T. M. Badger Dietary Soy Protein Isolate Attenuates Metabolic Syndrome in Rats via Effects on PPAR, LXR, and SREBP Signaling J. Nutr., August 1, 2009; 139(8): 1431 - 1438. [Abstract] [Full Text] [PDF]

				Y. Li, J. S. Ross-Viola, N. F. Shay, D. D. Moore, and M.-L. Ricketts Human CYP3A4 and Murine Cyp3A11 Are Regulated by Equol and Genistein via the Pregnane X Receptor in a Species-Specific Manner J. Nutr., May 1, 2009; 139(5): 898 - 904. [Abstract] [Full Text] [PDF]

				A. Bitto, D. Altavilla, A. Bonaiuto, F. Polito, L. Minutoli, V. Di Stefano, D. Giuliani, S. Guarini, V. Arcoraci, and F. Squadrito Effects of aglycone genistein in a rat experimental model of postmenopausal metabolic syndrome J. Endocrinol., March 1, 2009; 200(3): 367 - 376. [Abstract] [Full Text] [PDF]

				A. Orgaard and L. Jensen The Effects of Soy Isoflavones on Obesity Experimental Biology and Medicine, September 1, 2008; 233(9): 1066 - 1080. [Abstract] [Full Text] [PDF]

				A. A Thorp, P. R. Howe, T. A Mori, A. M Coates, J. D Buckley, J. Hodgson, J. Mansour, and B. J Meyer Soy food consumption does not lower LDL cholesterol in either equol or nonequol producers Am. J. Clinical Nutrition, August 1, 2008; 88(2): 298 - 304. [Abstract] [Full Text] [PDF]

				R. Villegas, Y.-T. Gao, G. Yang, H.-L. Li, T. A Elasy, W. Zheng, and X. O. Shu Legume and soy food intake and the incidence of type 2 diabetes in the Shanghai Women's Health Study Am. J. Clinical Nutrition, January 1, 2008; 87(1): 162 - 167. [Abstract] [Full Text] [PDF]

				S. Rayalam, M. A. Della-Fera, J.-Y. Yang, H. J. Park, S. Ambati, and C. A. Baile Resveratrol Potentiates Genistein's Antiadipogenic and Proapoptotic Effects in 3T3-L1 Adipocytes J. Nutr., December 1, 2007; 137(12): 2668 - 2673. [Abstract] [Full Text] [PDF]

				B. Sosic-Jurjevic, B. Filipovic, V. Ajdzanovic, D. Brkic, N. Ristic, M. M. Stojanoski, N. Nestorovic, S. Trifunovic, and M. Sekulic A BRIEF COMMUNICATION: Subcutaneously Administrated Genistein and Daidzein Decrease Serum Cholesterol and Increase Triglyceride Levels in Male Middle-Aged Rats Experimental Biology and Medicine, October 1, 2007; 232(9): 1222 - 1227. [Abstract] [Full Text] [PDF]

				Y. Li, O. Mezei, and N. F. Shay Human and Murine Hepatic Sterol-12-{alpha}-Hydroxylase and Other Xenobiotic Metabolism mRNA Are Upregulated by Soy Isoflavones J. Nutr., July 1, 2007; 137(7): 1705 - 1712. [Abstract] [Full Text] [PDF]

				E. S. Shin, H. H. Lee, S. Y. Cho, H. W. Park, S. J. Lee, and T. R. Lee Genistein Downregulates SREBP-1 Regulated Gene Expression by Inhibiting Site-1 Protease Expression in HepG2 Cells J. Nutr., May 1, 2007; 137(5): 1127 - 1131. [Abstract] [Full Text] [PDF]

				T. C. Rideout, Z. Yuan, M. Bakovic, Q. Liu, R.-K. Li, Y. Mine, and M. Z. Fan Guar Gum Consumption Increases Hepatic Nuclear SREBP2 and LDL Receptor Expression in Pigs Fed an Atherogenic Diet J. Nutr., March 1, 2007; 137(3): 568 - 572. [Abstract] [Full Text] [PDF]

				B. K. Chacko, R. T. Chandler, T. L. D'Alessandro, A. Mundhekar, N. K. H. Khoo, N. Botting, S. Barnes, and R. P. Patel Anti-Inflammatory Effects of Isoflavones are Dependent on Flow and Human Endothelial Cell PPAR{gamma} J. Nutr., February 1, 2007; 137(2): 351 - 356. [Abstract] [Full Text] [PDF]

				O. Mezei, Y. Li, E. Mullen, J. S. Ross-Viola, and N. F. Shay Dietary isoflavone supplementation modulates lipid metabolism via PPAR{alpha}-dependent and -independent mechanisms Physiol Genomics, September 14, 2006; 26(1): 8 - 14. [Abstract] [Full Text] [PDF]

				L Dubuquoy, C Rousseaux, X Thuru, L Peyrin-Biroulet, O Romano, P Chavatte, M Chamaillard, and P Desreumaux PPAR{gamma} as a new therapeutic target in inflammatory bowel diseases. Gut, September 1, 2006; 55(9): 1341 - 1349. [Full Text] [PDF]

				M. R. Peluso Flavonoids Attenuate Cardiovascular Disease, Inhibit Phosphodiesterase, and Modulate Lipid Homeostasis in Adipose Tissue and Liver Experimental Biology and Medicine, September 1, 2006; 231(8): 1287 - 1299. [Abstract] [Full Text] [PDF]

				M. Zang, S. Xu, K. A. Maitland-Toolan, A. Zuccollo, X. Hou, B. Jiang, M. Wierzbicki, T. J. Verbeuren, and R. A. Cohen Polyphenols Stimulate AMP-Activated Protein Kinase, Lower Lipids, and Inhibit Accelerated Atherosclerosis in Diabetic LDL Receptor-Deficient Mice. Diabetes, August 1, 2006; 55(8): 2180 - 2191. [Abstract] [Full Text] [PDF]

				V. Leray, B. Siliart, H. Dumon, L. Martin, R. Sergheraert, V. Biourge, and P. Nguyen Protein Intake Does Not Affect Insulin Sensitivity in Normal Weight Cats J. Nutr., July 1, 2006; 136(7): 2028S - 2030S. [Full Text] [PDF]

				D. Liu, W. Zhen, Z. Yang, J. D. Carter, H. Si, and K. A. Reynolds Genistein Acutely Stimulates Insulin Secretion in Pancreatic {beta}-Cells Through a cAMP-Dependent Protein Kinase Pathway. Diabetes, April 1, 2006; 55(4): 1043 - 1050. [Abstract] [Full Text] [PDF]

				P. Shen, M. H. Liu, T. Y. Ng, Y. H. Chan, and E. L. Yong Differential Effects of Isoflavones, from Astragalus Membranaceus and Pueraria Thomsonii, on the Activation of PPAR{alpha}, PPAR{gamma}, and Adipocyte Differentiation In Vitro J. Nutr., April 1, 2006; 136(4): 899 - 905. [Abstract] [Full Text] [PDF]

				H.-K. Kim, C. Nelson-Dooley, M. A. Della-Fera, J.-Y. Yang, W. Zhang, J. Duan, D. L. Hartzell, M. W. Hamrick, and C. A. Baile Genistein Decreases Food Intake, Body Weight, and Fat Pad Weight and Causes Adipose Tissue Apoptosis in Ovariectomized Female Mice J. Nutr., February 1, 2006; 136(2): 409 - 414. [Abstract] [Full Text] [PDF]

				B. K. Chacko, R. T. Chandler, A. Mundhekar, N. Khoo, H. M. Pruitt, D. F. Kucik, D. A. Parks, C. G. Kevil, S. Barnes, and R. P. Patel Revealing anti-inflammatory mechanisms of soy isoflavones by flow: modulation of leukocyte-endothelial cell interactions Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H908 - H915. [Abstract] [Full Text] [PDF]

				S. Kim, I. Sohn, Y. S. Lee, and Y. S. Lee Hepatic Gene Expression Profiles Are Altered by Genistein Supplementation in Mice with Diet-Induced Obesity J. Nutr., January 1, 2005; 135(1): 33 - 41. [Abstract] [Full Text] [PDF]

				L Hilakivi-Clarke, C Wang, M Kalil, R Riggins, and R G Pestell Nutritional modulation of the cell cycle and breast cancer Endocr. Relat. Cancer, December 1, 2004; 11(4): 603 - 622. [Abstract] [Full Text] [PDF]

				E. Mullen, R. M. Brown, T. F. Osborne, and N. F. Shay Soy Isoflavones Affect Sterol Regulatory Element Binding Proteins (SREBPs) and SREBP-Regulated Genes in HepG2 Cells J. Nutr., November 1, 2004; 134(11): 2942 - 2947. [Abstract] [Full Text] [PDF]

				C. Ascencio, N. Torres, F. Isoard-Acosta, F. J. Gomez-Perez, R. Hernandez-Pando, and A. R. Tovar Soy Protein Affects Serum Insulin and Hepatic SREBP-1 mRNA and Reduces Fatty Liver in Rats J. Nutr., March 1, 2004; 134(3): 522 - 529. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mezei, O. Articles by Shay, N. Search for Related Content PubMed PubMed Citation Articles by Mezei, O. Articles by Shay, N. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Substance via MeSH Medline Plus Health Information Diabetes Herbal Medicine